Sweeney–Cox Syndrome (SWCOS) — Comprehensive Research Report

Prepared: 2026-08-28 · Target: MONDO:0060592 · Category: Mendelian, autosomal dominant, craniofacial dysostosis/frontonasal dysplasia spectrum

Evidence-quality preamble (read first)

Sweeney–Cox syndrome is an ultra-rare, recently delineated entity with a total published cohort of three individuals. This dominates every section below. Two important consequences for knowledge-base curation:

1. Nearly every phenotype frequency is 1/2 or 2/2, derived from the two index patients in Kim et al. 2017. These are not population frequencies and must not be curated as if they were.
2. ClinGen's Craniofacial Malformations GCEP classified the TWIST1–Sweeney-Cox syndrome gene–disease relationship as Limited (3–4 points) in its 2026 round-one curation — the weakest of its three TWIST1 assertions. This is the single most important recent development for this entry and is stated verbatim below.

Throughout, I distinguish: - [CACHED] — quote verified against a file already in references_cache/ (usable as a dismech evidence snippet: as-is). - [WEB] — retrieved from a database or full text online during this session; the claim is sound but the exact string has not been verified against a fetched reference cache file and must be re-fetched with just fetch-reference before being quoted. - [UNVERIFIED] — flagged inference or a detail I could not independently confirm.

1. Disease Information

Overview

Sweeney–Cox syndrome (SWCOS) is an autosomal dominant congenital craniofacial dysostosis caused by de novo heterozygous missense substitution of a single highly conserved glutamic acid residue — Glu117 — in the basic DNA-binding domain of TWIST1. It sits at the frontonasal-dysplasia end of the TWIST1 phenotypic spectrum: patients have severe hypertelorism, deficient formation of the bony orbits and eyelids (upper eyelid colobomas, pseudoproptosis), nasal and midfacial hypoplasia, dysplastic ears, and a variable set of extracranial malformations. It is mechanistically and clinically distinct from Saethre–Chotzen syndrome (SCS), the classical TWIST1 haploinsufficiency disorder characterized by coronal craniosynostosis.

The disease was named for the two clinicians who contributed the index patients — E. Sweeney and H. Cox, both co-authors on the delineating paper.

Delineating publication:

"Here, we describe a new clinical entity, Sweeney-Cox syndrome, associated with distinct de novo amino acid substitutions (p.Glu117Val and p.Glu117Gly) at a highly conserved glutamic acid residue located in the basic DNA binding domain of TWIST1, in two subjects with frontonasal dysplasia and additional malformations." — Kim S, Twigg SRF, Scanlon VA, et al. Hum Mol Genet 2017;26(11):2118–2132. PMID:28369379, DOI 10.1093/hmg/ddx107 [CACHED]

Key identifiers

Synonyms and alternative names

• SWCOS (OMIM abbreviation)
• TWIST1-related Sweeney-Cox syndrome (ClinGen dyadic naming convention, used in Genet Med 2026)
• Descriptively referenced in the literature as "TWIST1 basic-domain (Glu117) frontonasal dysplasia" — not a formal synonym.
• Do not use "frontonasal dysplasia type 4" or similar — FND1/2/3 are the ALX3/ALX4/ALX1 entities and are distinct.

Source of information

Entirely aggregated disease-level and case-report literature. There is no EHR-derived cohort, no registry, no natural-history study, and no patient organization. All human phenotype data trace to three published individuals. HPO annotations for OMIM:617746 cite PMID:28369379 exclusively for every term [WEB — HPO/ontology.jax.org API].

2. Etiology

Primary causal factor

A single heterozygous de novo missense substitution at TWIST1 codon 117 (NM_000474.4), replacing a glutamic acid that makes base-specific contacts with the E-box DNA motif. No environmental, infectious, or multifactorial contribution is described or plausible.

Reported causal alleles (all three published patients):

⚠️ Nomenclature discrepancy worth flagging. The Takenouchi abstract states "c.351C>G p.Glu117Asp" [CACHED], but ClinVar represents the same protein change as c.351G>T (VCV002572412) [WEB]. The ClinVar representation is internally consistent (GAG→GAT); the published c.351C>G cannot yield Asp from a Glu codon under NM_000474.4. Per repo policy, never alter an identifier inside an evidence snippet — quote the paper as published and record the reconciliation in notes:.

Genetic risk factors

• Causal variant class: ultra-localized missense hotspot. Of ~100 TWIST1 mutations reported in SCS, none previously affected codon 117 [CACHED, PMID:28369379].
• Susceptibility loci / modifier genes: none identified. Sample size (n=3) precludes any modifier analysis.
• Family history: all three cases de novo; unaffected parents.
• Parental age effect: not assessed (n=3).

Environmental risk factors

None described. No toxin, teratogen, occupational, dietary, or infectious association has been reported or proposed. Sex distribution in the published cohort is 2 male : 1 female — not interpretable at this n.

Protective factors

None known. No protective variants, modifier alleles, or environmental exposures have been described. gnomAD does not report the Glu117 substitutions (consistent with de novo, fully penetrant severe disease) [UNVERIFIED — should be checked directly at gnomad.broadinstitute.org before curating as an allele-frequency claim].

Gene–environment interactions

Not applicable / none reported. This is a fully penetrant de novo dominant developmental disorder with no evidence of environmental modulation.

3. Phenotypes

The authoritative annotation set

The HPO disease annotation for OMIM:617746 contains 48 phenotype terms plus inheritance and clinical-course terms, all sourced to PMID:28369379, all with frequencies expressed as fractions of the two index patients [WEB — ontology.jax.org/api/network/annotation/OMIM:617746]. Reproduced in full below, since this is directly loadable into a dismech phenotypes: block.

Head and neck — craniofacial (the diagnostic core)

Ear

Eye

Note: pseudoproptosis (secondary to deficient bony orbits, accentuated by midface hypoplasia) is described in OMIM's clinical synopsis and the Arizona Hereditary Ocular Diseases entry but is not in the HPO annotation set [WEB]. Consider HP:0000520 Proptosis with an explanatory description making clear it is pseudoproptosis of orbital-volume origin, or leave unbound with prose — the mechanistic distinction matters and no HPO term captures it cleanly.

Nervous system

Limbs and skeletal

Cardiovascular / haematologic

Digestive / genitourinary

Skin, hair, nails / prenatal

Course and inheritance

Phenotypes reported in the third patient (Takenouchi 2018) — NOT in the HPO annotation set

The p.Glu117Asp patient extends the phenotype and is the key to the SWCOS↔SCS boundary:

"Herein, we document a male infant with the distinctive facial features of ablepharon, hypertelorism, cheek pads adjacent to the corners of the mouth, and bilateral coronal suture craniosynostosis who had a de novo heterozygous mutation in the basic domain of TWIST1, that is, c.351C>G p.Glu117Asp." — PMID:30450715 [CACHED]

Additional HP suggestions for this patient (verify all with just validate-terms / OAK before binding): - HP:0004440 Coronal craniosynostosis [UNVERIFIED ID] - HP:0001363 Craniosynostosis (parent term, safer) - Ablepharon — no confident HPO ID; HP:0000636 Upper eyelid coloboma understates it. Consider free-text preferred_term with no term: binding rather than manufacturing a match (per the repo's "no term beats a bad one" rule). - Cheek pads adjacent to the corners of the mouth — shared with Barber–Say and ablepharon–macrostomia syndromes; no clean HPO term. Free text recommended.

Phenotype characteristics

• Age of onset: congenital in 3/3 (HP:0003577). Malformations are established during embryonic craniofacial morphogenesis (~weeks 4–8); the phenotype is fully expressed at birth.
• Severity: variable but uniformly severe facially. Subject 2 (p.Glu117Gly) was markedly more severe than Subject 1 (p.Glu117Val): she required tracheostomy from birth, had cardiac defects, asplenia, and progressed to corneal scarring with phthisis of the right eye despite lid coloboma repair [WEB — PMC5438873; Arizona HOD].
• Progression: the malformation burden is static/non-progressive — it is a structural dysostosis, not a degenerative process. What does progress is secondary/complication morbidity: corneal exposure keratopathy → scarring → phthisis bulbi; conductive hearing loss; feeding/airway compromise; and, in the E117D patient, craniosynostosis with its attendant risk of raised intracranial pressure.
• Frequency among affected: see tables. Facial features (hypertelorism, upper eyelid coloboma, prominent metopic ridge, broad nasal tip) and global developmental delay are 2/2; everything else is 1/2.

Quality-of-life impact

No formal QoL instrument (EQ-5D, PROMIS, SF-36) has ever been administered. Per-phenotype impacts inferred from the case descriptions [WEB]:

4. Genetic / Molecular Information

Causal gene

Protein architecture and the Glu117 hotspot

• bHLH domain: residues 108–159 (UniProt Q15672 FT DOMAIN) [WEB].
• Residues 1–105: disordered; residues 161–191: sufficient for transactivation [WEB].
• Glu117 lies within the basic (DNA-contacting) region at the N-terminal end of the bHLH fold. Sequence context around it (positions 111–120): V M A N V R E R Q R — i.e. E117 flanked by the basic arginines R116/R118/R120. (R120G is an independently reported pathogenic SCS/craniosynostosis allele, ClinVar VCV001474221 [WEB] — underlining that this short stretch is a mutational hotspot for two mechanistically different diseases.)
• Functional role of the conserved glutamate: it makes the sequence-specific base contacts that define E-box recognition:

"is responsible for the sequence-specific contacts of adjacent bases (CA) that constitute the symmetrical E box binding motif CANNTG" — Kim et al. 2017 full text [WEB — PMC5438873]

• Structural resource: PDB 8OSB — "TWIST1-TCF4-ALX4 complex on specific DNA", X-ray, 2.90 Å, residues 101–167 [WEB — UniProt/RCSB]. This is the directly relevant structure for modelling the Glu117 substitutions, and it captures TWIST1 in the ternary arrangement that the Coordinator-motif biology (§6) predicts.

Variant classification and population frequency

ClinVar records at codon 117 and immediate neighbours [WEB — NCBI E-utilities]:

Two curation-relevant observations: 1. p.Glu117Ter (nonsense) is annotated to Saethre–Chotzen/craniosynostosis, not Sweeney-Cox — exactly as the mechanism predicts. Truncation at 117 = loss of allele = haploinsufficiency = SCS. Missense at 117 = poisoned protein = SWCOS. The same codon produces two different diseases by two different mechanisms. This is a clean, curatable mechanistic contrast. 2. ClinVar's condition assignment is inconsistent — p.Glu117Gly, one of the two original SWCOS alleles, is filed under "TWIST1-related craniosynostosis; Saethre-Chotzen syndrome." Do not treat ClinVar's condition field as authoritative for SWCOS membership; use the primary literature.

• Variant type: all missense (single-nucleotide substitution).
• Origin: germline, de novo in 3/3. No somatic involvement; no mosaicism reported.
• Allele frequency: absent from population databases (expected for de novo severe dominant disease) [UNVERIFIED — confirm in gnomAD directly].

Functional consequence — the central mechanistic claim

Antimorphic (dominant-negative), not loss-of-function. This is the defining molecular statement about the disease and it is asserted independently in two cached papers:

"The genetic analysis favors a predominantly dominant-negative mechanism for the action of amino acid substitutions at this highly conserved glutamic acid residue" — PMID:28369379 [CACHED]

"Heterozygous localized TWIST1 and TWIST2 basic domain substitutions exert antimorphic effects to cause Sweeney-Cox syndrome, Barber-Say syndrome, and ablepharon-macrostomia syndrome, respectively." — PMID:30450715 [CACHED]

For dismech schema purposes: - On GeneticContext: functional_impact_category: DOMINANT_NEGATIVE — this is the variant-consequence slot and it is the right one here. - Do not use LOSS_OF_FUNCTION; that is the SCS mechanism and conflating them erases the whole point of the entity.

Modifier genes

None identified. Candidate modifiers on mechanistic grounds only (no human data): TCF12 (HGNC:11623, the obligate E-protein partner, itself a coronal craniosynostosis gene), TCF3/E12, HAND2, and the homeodomain Coordinator partners ALX1, ALX4, MSX1, PRRX1. All speculative — do not curate as modifiers.

Epigenetic information

No disease-specific DNA-methylation, histone, or chromatin dataset exists for SWCOS patients. However, TWIST1's own molecular action is chromatin-level: it drives chromatin opening and H3K27 acetylation at Coordinator-motif enhancers in cranial neural crest cells (§6). A Glu117 substitution is therefore expected to produce a genome-wide enhancer-accessibility defect in CNCCs — a testable and completely unexplored hypothesis, and a good candidate for a KNOWLEDGE_GAP discussion in the entry.

Chromosomal abnormalities

Not a mechanism for SWCOS. Note for differential purposes: 7p21 deletions encompassing TWIST1 cause SCS (haploinsufficiency), and a 430 kb duplication involving TWIST1 regulatory elements causes auriculocondylar syndrome [WEB — PMC9411924]. Neither produces the SWCOS phenotype, again because SWCOS requires a poisoned protein, not altered dosage.

5. Environmental Information

• Environmental factors: none. No toxicological, radiation, pollution, or occupational association reported. CTD contains no SWCOS-specific chemical–disease association.
• Lifestyle factors: none. No maternal smoking, alcohol, folate, or nutritional association has been reported or investigated (n=3 precludes it).
• Infectious agents: not applicable.

Curation guidance: the environmental: section should be left empty, or, if a curator wishes to record that the search was performed, use the sanctioned waiver form — review_notes: beginning exactly Left deliberately uncited. followed by ≥20 words describing the searches run (CTD, PubMed teratogen queries, EPA) and why nothing quotable was found.

6. Mechanism / Pathophysiology

This is the richest section of the entry and where SWCOS earns its place in a mechanism knowledge base. The causal chain is unusually well-supported for an n=3 disease because the gene is deeply studied even though the disease is not.

6.1 The causal chain (upstream → downstream)

[1] De novo heterozygous TWIST1 c.350A>T / c.350A>G / c.351G>T
↓  (MOLECULAR)
[2] Glu117 substitution in the bHLH basic region
↓  (MOLECULAR)
[3] Loss/degradation of sequence-specific E-box (CANNTG) recognition,
    with RETAINED dimerization and residual DNA binding
↓  (MOLECULAR)
[4] Mutant protein sequesters wild-type TWIST1 and E-proteins (TCF3/TCF12)
    into NON-PRODUCTIVE heterodimers  →  DOMINANT-NEGATIVE
↓  (MOLECULAR)
[5] Failure of TWIST1-dependent Coordinator-motif enhancer activation
    (chromatin opening + H3K27ac) in cranial neural crest cells
↓  (CELLULAR)
[6] Failure to activate the frontonasal ectomesenchyme program —
    ALX1, ALX3, ALX4 not induced in the frontonasal prominence
↓  (CELLULAR)
[7] Impaired CNCC EMT, migration, survival, and skeletogenic differentiation
↓  (TISSUE)
[8] Deficient frontonasal / periocular / orbital / nasal skeletal
    and soft-tissue morphogenesis
↓  (ORGANISM)
[9] Hypertelorism, deficient bony orbits with pseudoproptosis, eyelid
    colobomas, nasal hypoplasia, cleft palate/VPI, dysplastic ears

A parallel branch, dose-dependent, explains why one allele adds craniosynostosis:

[3'] Milder antimorphic effect (p.Glu117Asp)  →  net activity close to
     the haploinsufficient (SCS) range  →  coronal suture boundary
     failure  →  bicoronal craniosynostosis IN ADDITION to the
     SWCOS facial phenotype

"The present observation suggests that a localized TWIST1 basic domain substitution, that is, p.Glu117Asp, in TWIST1 may exert a mild antimorphic effect similar to that of haploinsufficiency, leading to craniosynostosis and ablepharon." — PMID:30450715 [CACHED]

6.2 The dosage-continuum model (the key conceptual contribution)

Kim et al. propose that TWIST1/TWIST2 basic-domain phenotypes lie on a single continuum of residual protein activity, and that the identity of the substituting amino acid sets the position on that continuum:

"phenotypes of individuals who are heterozygous for TWIST1 or TWIST2 mutations fall on a continuum" — correlating with protein activity levels; SWCOS alleles produce more severe dominant-negative effects than haploinsufficient SCS mutations, potentially reducing functional protein below the threshold required for neural crest survival [WEB — PMC5438873]

This makes SWCOS a textbook allelic-series / threshold disorder and is worth modelling explicitly as a mechanistic_hypotheses group in the dismech entry.

The TWIST2 comparison is from Marchegiani et al., Am J Hum Genet 2015, PMID:26119818: AMS = p.Glu75Lys; BSS = p.Glu75Gln or p.Glu75Ala; "the two syndromes differed based solely upon the nature of the substituting amino acid" [WEB].

6.3 Molecular pathways and protein dysfunction

TWIST1 normal function (UniProt Q15672):

"Efficient DNA binding requires dimerization with another bHLH protein. Homodimer or heterodimer with E proteins such as TCF3." … "Regulates cranial suture patterning and fusion." [WEB]

Why a basic-domain missense is worse than a null. The mutant retains its HLH dimerization surface but has a corrupted DNA-reading head. It therefore continues to titrate the limited pool of wild-type TWIST1 and E-proteins into complexes that occupy or fail at target enhancers:

mutant proteins likely "sequester WT protein in non-productive heterodimers comprising either HLH-2/HLH-8-Glu29† or HLH-8/HLH-8-Glu29†" [WEB — PMC5438873]

The Coordinator motif — the highest-resolution account of what Glu117 actually does. Bhatt/Kim et al., Cell 2024 (PMID:38262408) showed that a composite DNA element called the Coordinator — an E-box plus a homeodomain TAAT site separated by a 6-bp spacer — "guides cooperative and selective binding between the bHLH family mesenchymal regulator TWIST1 and a collective of HD factors" [WEB]. Mechanistically:

TWIST1 binds the E-box, drives chromatin opening, promotes homeodomain recruitment of ALX1, ALX4, MSX1 or PRRX1, and promotes enhancer acetylation at the coordinator motif [WEB]

Because Glu117 is precisely the residue that reads the E-box half of the Coordinator, a Glu117 substitution should collapse the entire cooperative assembly, not merely weaken one contact. This provides a direct, structure-anchored explanation for the frontonasal specificity of SWCOS, and PDB 8OSB (TWIST1–TCF4–ALX4 on DNA) is the corresponding structure.

Direct downstream target — Alx1. A 2026 paper (already in the local reference cache) closes the loop from TWIST1 to the frontonasal-dysplasia gene program:

"ECR1, whose homologous region in the human genome harbors a lead single nucleotide variation significantly associated with facial and cranial vault shape differences, exhibits high enrichment of Twist1 transcription factor occupancy in mouse embryonic frontonasal tissues and drove Twist1-dependent reporter transgene expression specifically in the developing periocular and frontonasal mesenchyme in transgenic mice." — Huang Y, Iyyanar PPR, Xu J, et al. Dev Biol 2026. PMID:41850652 [CACHED]

and, framing SWCOS explicitly:

"Mutations in TWIST1 have been associated with Sweeney-Cox (OMIM 617746) and Saethre-Chotzen (OMIM 101400) syndromes, with Sweeney-Cox syndrome characterized by hypertelorism with severe deficiency in frontal bones and hypoplasia of the nose and facial bones while Saethre-Chotzen syndrome exhibits craniosynostosis with hypertelorism and maxillary hypoplasia" — PMID:41850652 [CACHED]

"mice with lineage-specific inactivation of Twist1 in migrating neural crest cells, exhibited dramatic loss of Alx1 mRNA expression in the developing frontonasal CNCCs" — PMID:41850652 [CACHED]

This is the mechanistic bridge that makes SWCOS a frontonasal dysplasia: biallelic ALX1 loss causes FND3 (OMIM 613456) with severe midfacial hypoplasia and extreme microphthalmia; TWIST1 sits directly upstream of ALX1 through the ECR1 enhancer; so a dominant-negative TWIST1 phenocopies part of the ALX program. Curate this as an explicit causal edge.

Dimer-selection / phosphorylation axis (SCS-derived, mechanistically adjacent). Twist1–Hand2 dimer choice is modulated by PKA and PP2A phosphorylation of conserved helix-I residues, and multiple SCS-associated TWIST1 mutations alter this [WEB — PMC2568820, Firulli et al.]. Glu117 is in the basic region rather than the helices, so this is a different route to the same "dimer misallocation" endpoint — worth noting but do not conflate.

6.4 Cellular processes

The critical modelling insight: GO:0070888 E-box binding is DECREASED/LOSS_OF_FUNCTION while GO:0046983 protein dimerization activity is UNCHANGED. That dissociation is the disease mechanism, and a well-built dismech entry should make it visible as two separate molecular_functions descriptors on the same or adjacent nodes.

Direct quotes available for CNCC biology:

"Twist1 suppresses Irf6 and other epithelial genes in CNCCs during the epithelial-to-mesenchymal transition (EMT) process and cell migration. Conversely, a loss of Twist1 leads to a sustained expression of epithelial and cell adhesion markers in migratory CNCCs." — Bertol JW, et al. Development 2022. PMID:35781329 [CACHED]

"TWIST1 has been shown to promote cell survival and proliferation of migratory CNCCs during craniofacial development" — PMID:35781329 [CACHED]

"Loss of Twist1 in neural crest cells and their derivatives impairs skeletogenic differentiation and leads to the loss of bones of the snout, upper face and skull vault." — Bildsoe H, et al. Dev Biol 2009. PMID:19414008 [CACHED]

6.5 Systems not involved

• Metabolic changes: none. Not a metabolic disease; no enzyme deficiency, no biochemical marker.
• Immune system involvement: none, despite TWIST1's known repression of TNF/IL1B in other contexts (UniProt) — no immunologic phenotype has been reported in any SWCOS patient. Note the 1/2 asplenia: this is a structural developmental defect (laterality/mesoderm-derived organ agenesis), and it does carry a real functional-asplenia infection risk (see §11/§13), but it is not evidence of a primary immune mechanism.
• Tissue damage mechanisms: SWCOS is a dysmorphogenesis, not a tissue-injury disease. There is no oxidative stress, ischemia, fibrosis, or necrosis component. The only genuine "tissue damage" is secondary corneal exposure injury from the eyelid defect (documented: corneal scarring → phthisis bulbi).
• Biochemical abnormalities: none. No diagnostic lab abnormality exists.

6.6 Molecular profiling

No SWCOS-patient omics data exist — no transcriptomics, proteomics, metabolomics, lipidomics, or single-cell data from any of the three patients.

Relevant gene-level datasets that could be re-used with clear labelling as model/normal-development data (not patient data), all GEO [WEB, via PMID:41850652]:

⚠️ Dataset-curation caution. Per the repo's dataset SOP, these are not Sweeney-Cox datasets. A gene-driven search for TWIST1 returns craniosynostosis, EMT, and cancer datasets — classic GENE_ONLY / Named Entity Confusion territory. If curated at all, they must be tagged as mouse developmental resources with explicit provenance notes, never as disease datasets. Run just verify-datasets on anything added.

Functional genomics / dosage. A 2025 Cell Genomics study examined "how concentrations of the dosage-sensitive TFs TWIST1 and SOX9 affect regulatory element chromatin accessibility in facial progenitor cells" (PMID:40020686) [WEB] — directly relevant to the threshold model in §6.2 and the best available quantitative handle on TWIST1 dose-response.

7. Anatomical Structures Affected

Organ level

Primary (2/2 or 3/3 involvement): - Craniofacial skeleton — frontal bones, bony orbits (deficient, producing pseudoproptosis), nasal bones/capsule, maxilla, palate - Eyelids — upper lid colobomas; ablepharon in the E117D patient - Nose — hypoplastic alae, short/low columella, broad tip - External ear — microtia, crumpled/cupped, low-set, overfolded helix - Palate / velopharynx

Secondary and variable (1/2): - CNS — cerebellar hypoplasia; global developmental delay in 2/2 - Cardiovascular — PDA, PFO - Spleen — asplenia - GI — anal atresia, GERD - GU — bilateral cryptorchidism - Limbs — hands (syndactyly, long fingers, short distal phalanges), feet (talipes equinovarus, 2-5 toe syndactyly) - Thorax — narrow chest, short clavicles - Airway — choanal atresia; tracheostomy dependence

Body systems: skeletal (craniofacial predominant), visual/ocular adnexal, auditory, nervous, cardiovascular, digestive, genitourinary, lymphoid/splenic, respiratory (upper airway).

Tissue and cell level

The single defining cell type is the cranial neural crest cell and its ectomesenchymal derivatives. Bildsoe et al. showed the requirement is not uniform across derivatives:

"Since Twist1 is expressed in the tissues of the maxillary eminence and the mandibular arch, this finding suggests that the requirement for Twist1 is not the same in all neural crest derivatives." — PMID:19414008 [CACHED]

And a non-cell-autonomous component reaches mesoderm-derived bone:

"The effect of the loss of Twist1 function is not restricted to neural crest-derived bones, since the predominantly mesoderm-derived parietal and interparietal bones are also affected, presumably as a consequence of lost interactions with neural crest-derived tissues." — PMID:19414008 [CACHED]

CL suggestions (verify every one with just validate-terms before binding):

Tissue types: neural crest–derived ectomesenchyme (connective/skeletal), membranous bone, cartilage, and — for the eyelid — surface ectoderm-derived structures whose development depends on the underlying mesenchyme.

Subcellular level

• GO:0005634 nucleus — normal site of TWIST1 action; where the dominant-negative complexes form.
• GO:0090575 RNA polymerase II transcription regulator complex.
• Unexpected non-nuclear pool: TWIST1 is also found in apical endocytic vesicles in the neuroepithelium and physically interacts with β- and δ-catenin:

  "TWIST1 is expressed in endocytic vesicles at the apical surface and interacts with β/δ-catenins during neural tube closure" — PMID:35781329 [CACHED]

Relevant GO: GO:0030139 endocytic vesicle; GO:0016342/adherens-junction associations. Whether a Glu117 substitution affects this cytoplasmic pool is completely unknown — a good KNOWLEDGE_GAP.

Localization

UBERON suggestions — treat ALL as leads requiring OAK verification (uv run runoak -i sqlite:obo:uberon info "l^<label>"): - face, head, nose, orbit / orbital region, eyelid, external ear, palate, mandible, maxilla, frontal bone, skull vault, coronal suture, frontonasal prominence, neural crest, spleen, anus, testis, limb.

Lateralization: predominantly bilateral and symmetric — bilateral upper eyelid colobomas, bilateral talipes, bilateral cryptorchidism, bilateral coronal synostosis (E117D patient), bilateral syndactyly. Asymmetry is not a feature (contrast Saethre–Chotzen, where facial asymmetry is characteristic — a useful differential discriminator).

8. Temporal Development

Onset

• Congenital — HP:0003577, 2/2. Malformations are complete at birth.
• Embryologic critical window: cranial neural crest specification, delamination, migration, and frontonasal patterning — approximately weeks 3–8 of human gestation (mouse E8.5–E11.5, the window across which the Twist1 phenotypes are established).
• Prenatal detectability: polyhydramnios in 1/2. Severe hypertelorism, orbital deficiency and nasal hypoplasia are in principle detectable on second-trimester ultrasound, but no prenatally diagnosed case has been published.
• Onset pattern: not acute/subacute/chronic — it is a structural developmental anomaly, present ab initio.

Progression

• Disease course: stable / non-progressive for the primary malformations. There is no degeneration, no relapsing-remitting pattern, no end-stage.
• What does change over time is complication burden. Documented trajectory in Subject 2: eyelid coloboma → surgical repair → corneal scarring → phthisis of the right eye [WEB — PMC5438873, Arizona HOD]. This is treatment-modifiable secondary damage, not disease progression, and should be modelled as a downstream complication edge rather than a progression: phase.
• In the E117D patient, craniosynostosis introduces the one genuinely time-critical element: untreated bicoronal synostosis risks raised intracranial pressure and requires surgical release in infancy.
• Duration: lifelong.
• Progression rate: not applicable.

Patterns

• Remission: none — the concept does not apply.
• Critical periods for intervention:
• Neonatal (days): airway (tracheostomy for choanal atresia/airway compromise), imperforate anus (colostomy/anoplasty), corneal protection — arguably the most time-critical and most under-appreciated, since sight loss is preventable.
• Infancy (0–12 mo): cranial vault surgery if synostosis present; hearing assessment and amplification (language window).
• Early childhood: palate repair / VPI management for speech; syndactyly release; orchidopexy.
• Childhood–adolescence: staged craniofacial and orbital reconstruction; ongoing developmental support.

9. Inheritance and Population

Epidemiology

• Prevalence: not established. No Orphanet prevalence class; no registry; no population estimate anywhere in the literature.
• Total published cases: 3 (2 in Kim 2017; 1 in Takenouchi 2018).
• Incidence: unknown.

Recommended dismech Prevalence record (per the structured-prevalence policy in CLAUDE.md — do not use the deprecated free-text percentage):

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Three published individuals as of August 2026 (two in the delineating
    report, one subsequent case). No prevalence or incidence estimate has
    been published; no Orphanet epidemiology record exists.

Do not populate rate_per_100000 — there is no numeric estimate to normalize, and inventing one would be fabrication.

Genetic parameters

• Inheritance: Autosomal dominant (HP:0000006), all cases de novo. Confirmed across sources including the Asian craniosynostosis series:

  "The pattern of inheritance is autosomal dominant in Saethre-Chotzen syndrome, Robinow-Sorauf syndrome, and Sweeney-Cox syndrome." — Dhiman S, et al. J Pediatr Genet 2024. PMID:39502847 [CACHED]

• Penetrance: presumed complete — 3/3 carriers affected, all severely. No unaffected carrier has been reported. (With n=3 and no transmitting parents, this is an assumption, not a measurement.)
• Expressivity: variable, and — importantly — the variability tracks the substituting amino acid rather than being stochastic. Val vs Gly vs Asp gives three distinguishable severity/feature profiles.
• Recurrence risk: for parents of a de novo proband, low but not zero (gonadal mosaicism cannot be excluded); for an affected individual, 50%. No SWCOS patient has reproduced, so vertical transmission has never been observed.
• Genetic anticipation: not applicable (not a repeat expansion).
• Germline mosaicism: not reported; theoretically possible.
• Founder effects: none — three unrelated individuals, three different substitutions.
• Consanguinity: irrelevant (dominant, de novo).
• Carrier frequency: not applicable.

Population demographics

• Affected populations: no ethnic predilection. Reported patients came from UK-based clinical genetics services (Kim 2017, contributed by E. Sweeney and H. Cox) and Japan (Takenouchi 2018) — consistent with ascertainment through specialist craniofacial centres rather than any population enrichment.
• Geographic distribution: no clustering; sporadic worldwide.
• Variant geography: none — each allele reported once.
• Sex ratio: 2 male : 1 female. Not interpretable; no sex bias is expected for an autosomal dominant de novo condition. Do not curate a sex ratio.
• Age distribution: all identified in infancy/childhood. No adult SWCOS patient has been described in the literature, so nothing is known about the adult phenotype.

10. Diagnostics

The diagnostic pathway in one sentence

Recognition of the characteristic facial gestalt → molecular confirmation of a TWIST1 codon-117 missense variant. There is no biochemical or imaging test that makes the diagnosis.

Clinical tests

• Laboratory tests: none diagnostic. No enzyme assay, metabolite, or blood/urine marker. No LOINC-codable disease-specific analyte exists.
• Biomarkers: none. The only "biomarker" is the genotype.
• Imaging:
• Craniofacial CT with 3D reconstruction — the key structural study; defines orbital bone deficiency, suture status, and midface hypoplasia. Takenouchi et al. used spiral CT (MeSH keyword "Tomography, Spiral Computed" on the PubMed record, [CACHED]).
• Brain MRI — for cerebellar hypoplasia (1/2) and developmental-delay workup.
• Echocardiography — PDA/PFO.
• Abdominal ultrasound — essential, to detect asplenia, which is otherwise silent and carries real infection risk.
• Ophthalmic assessment including corneal examination — for exposure keratopathy.
• Functional tests: audiologic assessment (conductive loss); speech/VPI evaluation (nasendoscopy, videofluoroscopy).
• Electrophysiology: electrodiagnostic testing was normal in Subject 1 despite small eyes and no vision concerns [WEB — Arizona HOD]. ECG as part of cardiac workup.
• Biopsy / histopathology: no role. No characteristic histopathology has been described. Do not curate a histopathology: block.

Genetic testing — the diagnostic modality

Critical interpretive point: because SWCOS and SCS are caused by variants in the same gene, at the same codon, the report must specify the variant, not just the gene. A laboratory report reading "pathogenic TWIST1 variant → Saethre-Chotzen syndrome" is a real misdiagnosis risk — and ClinVar's own condition assignment for p.Glu117Gly demonstrates it happening in practice (§4).

Omics-based diagnostics

None applicable. No RNA-seq, proteomic, metabolomic, epigenomic (methylation episignature), or liquid-biopsy test exists or is under development for SWCOS. A DNA-methylation episignature has not been sought — a plausible but purely speculative future avenue given n=3.

Clinical criteria

No formal diagnostic criteria, consensus statement, or society guideline exists. Diagnosis is: characteristic facial gestalt + confirmed TWIST1 codon-117 missense.

Proposed working gestalt (synthesized from the 3 published patients — explicitly not a validated criterion set): 1. Marked hypertelorism, and 2. Upper eyelid coloboma or ablepharon with deficient bony orbits/pseudoproptosis, and 3. Nasal hypoplasia (hypoplastic alae, short columella, broad tip), and 4. De novo heterozygous TWIST1 p.Glu117 missense substitution.

Differential diagnosis

The framing from Takenouchi is the cleanest single statement of the differential:

"Sweeney-Cox syndrome, Barber-Say syndrome, and ablepharon-macrostomia syndrome share the facial features of ablepharon, hypertelorism, underdevelopment of the eyelids, and cheek pads adjacent to the corners of the mouth." — PMID:30450715 [CACHED]

"Our review showed that Sweeney-Cox syndrome appears to share many characteristics with Barber-Say syndrome and ablepharon-macrostomia syndrome except for craniosynostosis, which is a cardinal feature of Saethre-Chotzen syndrome." — PMID:30450715 [CACHED]

Screening

• Newborn screening: not applicable and not appropriate (no treatable metabolic component).
• Carrier screening: not applicable (de novo dominant).
• Cascade screening: not applicable (no familial cases).
• Prenatal testing: available on request for a couple with a previously affected child — targeted testing for the known familial variant by amniocentesis/CVS, or PGT-M. Recurrence risk is low (gonadal mosaicism only), so this is a counselling decision rather than a recommendation.

11. Outcome / Prognosis

All prognostic statements below are extrapolations from three patients. There is no survival data, no natural-history study, and no cohort. Curate accordingly.

Survival and mortality

• Survival rate (5-/10-year/overall): unknown — no data. All three published patients were alive at report.
• Life expectancy: not established. Not obviously reduced by the malformation complex itself in the absence of lethal cardiac or CNS anomalies, but the two known severe-end features that plausibly affect it are (a) airway compromise requiring tracheostomy and (b) asplenia, which confers lifelong overwhelming-post-splenectomy-infection–type risk if unrecognized.
• Mortality rate / disease-specific mortality: no data.
• Note on the allelic series: Takenouchi raises the possibility that some codon-117 substitutions may be lethal and therefore unascertained:

  "This suggests that any amino acid substitutions at Glu117 would likely lead to the Sweeney-Cox syndrome phenotype or lethality." — PMID:30450715 [CACHED]

This is a strong candidate for an ascertainment-bias discussions entry: the three living patients may represent the survivable tail of the allelic series.

Morbidity and function

• Developmental outcome: global developmental delay in 2/2; moderate learning disability documented in Subject 1 [WEB — PMC5438873]. Whether delay is intrinsic (cerebellar hypoplasia, CNS involvement) or partly secondary (hearing loss, prolonged hospitalization, tracheostomy) is unresolved — a genuine knowledge gap.
• Sensory outcome: conductive hearing loss (1/2); vision loss from corneal exposure is documented and is the most clearly preventable morbidity (phthisis of the right eye in Subject 2 despite lid repair).
• Communication: delayed speech and language; velopharyngeal insufficiency and cleft palate compound this.
• Disability outcomes: surgical burden across craniofacial, ophthalmic, ENT, orthopaedic, urologic and colorectal domains; long-term multidisciplinary dependence.
• Quality-of-life measures: never assessed with any instrument.

Complications

Airway obstruction; exposure keratopathy → corneal scarring → phthisis bulbi; recurrent otitis media / conductive hearing loss; feeding difficulty and GERD; speech impairment from VPI; infection risk from asplenia; raised intracranial pressure if craniosynostosis is untreated; anaesthetic risk from difficult airway across repeated surgeries.

Recovery potential

The structural anomalies are not recoverable, only reconstructable. Functional outcomes for airway, feeding, hearing and speech are substantially improvable with timely intervention; vision is preservable only if corneal protection is instituted early.

Prognostic factors

Entirely inferential, but the strongest candidate is the identity of the substituting amino acid at codon 117 — the same variable that drives the phenotypic continuum. On current evidence: Asp → milder antimorph, adds synostosis; Val → intermediate; Gly → most severe (tracheostomy, cardiac defects, asplenia, eye loss). n=1 per allele. This is a hypothesis, not a genotype–phenotype rule, and should be curated with status: EMERGING if modelled as a mechanistic_hypotheses group.

Other plausible prognostic factors: presence of asplenia, presence of cardiac defect, degree of airway compromise, timeliness of corneal protection.

Prognostic biomarkers

None.

12. Treatment

The honest summary

There is no disease-modifying therapy, no drug, no clinical trial, and no published management guideline for Sweeney-Cox syndrome. Management is entirely symptomatic, surgical, and supportive, delivered by a multidisciplinary craniofacial team. The Arizona Hereditary Ocular Diseases entry states it plainly: no specific treatment exists for the underlying condition; individual malformations receive targeted care [WEB].

Pharmacotherapy

None. No drug targets the mechanism. No pharmacogenomic considerations. Leave therapeutic_agent absent throughout.

Surgical and interventional (the mainstay)

therapeutic_modality: SURGERY for all of the above (mechanically inferable from the NCIT surgical-action terms per the CLAUDE.md backfill table); DEVICE for hearing aids and tracheostomy hardware, which cannot be inferred mechanically and needs a per-entry decision.

Supportive and rehabilitative

The asplenia management item is worth curating explicitly: it is standard of care for asplenia generally (penicillin prophylaxis + pneumococcal/meningococcal/Hib vaccination), it is genuinely life-saving, and it is easy to miss in a patient whose clinical attention is dominated by the face.

Advanced therapeutics

• Gene therapy / gene editing: none for SWCOS. Conceptually, a dominant-negative allele is an allele-specific silencing target (ASO or siRNA knockdown of the mutant transcript, or base editing of the c.350/c.351 substitution) — but the disease is established embryonically, so postnatal correction cannot reverse existing dysmorphogenesis. This is a fundamental, not merely practical, barrier and should be stated as such rather than presented as a pipeline.
• A relevant adjacent result: RNA nanoparticle gene therapy has been used successfully in Twist1 mutant mice — PEGylated-peptide nanoparticles delivering plasmid DNA expressing miR-200a, injected subscalp at P7–P10, inhibited premature suture fusion, increased Gli1⁺/Six2⁺ suture stem cells, and sustained the effect to 56 days (Science Advances 2025) [WEB — PMC12372882].

  ⚠️ This targets craniosynostosis in a Twist1-haploinsufficient (SCS) model, not Sweeney-Cox. It is postnatal suture biology, not embryonic frontonasal patterning, and it would not address the SWCOS phenotype. Cite it only with that scope explicitly stated, and grade it evidence_source: MODEL_ORGANISM.

• Cell therapy, RNA therapies, targeted therapy, immunotherapy: none applicable.

Experimental treatments / clinical trials

Zero. A search of ClinicalTrials.gov and ICTRP returns no interventional or observational study for Sweeney-Cox syndrome. The clinical_trials: block should be empty.

Treatment outcomes, algorithms, personalized medicine

• Response rates: no data.
• Adverse events: those of the individual procedures; the cumulative anaesthetic risk of a difficult airway across many operations is the notable syndrome-specific concern.
• Treatment algorithms: none published. Care follows general craniofacial-team principles.
• Combination therapy / genotype-guided treatment: not applicable — genotype currently informs prognosis and counselling only, not therapy choice.

13. Prevention

Primary prevention

Not possible. De novo dominant variants are not preventable by any known intervention. There is no modifiable risk factor, no periconceptional supplement, and no exposure to avoid.

Secondary prevention (early detection)

This is where prevention is actually meaningful in SWCOS — not preventing the disease, but preventing its avoidable sequelae:

1. Corneal protection from day one. The documented loss of an eye to exposure keratopathy in Subject 2 is the strongest argument in the literature for aggressive, immediate ocular surface management in any infant with eyelid coloboma/ablepharon.
2. Abdominal ultrasound to detect asplenia, followed by prophylaxis and immunization.
3. Newborn hearing screening and ongoing audiologic surveillance.
4. Cranial imaging for suture status — the E117D case establishes that craniosynostosis can accompany SWCOS, so it should be actively excluded rather than assumed absent, with ICP surveillance if present.
5. Airway assessment for choanal atresia at birth.
6. Developmental surveillance from infancy.

Tertiary prevention

Staged reconstructive surgery to prevent functional deterioration; ICP monitoring; speech therapy to prevent entrenched articulation patterns; antibiotic prophylaxis for asplenia; dental and orthodontic follow-up given midface hypoplasia.

Immunization

Routine childhood schedule, plus asplenia-indicated vaccines (pneumococcal, meningococcal, Hib) where asplenia is present. There is no SWCOS-specific vaccine.

Genetic screening and counselling

• Population/carrier screening: not applicable.
• Prenatal testing / PGT-M: available for the known familial variant after an affected child; recurrence risk low (gonadal mosaicism only).
• Genetic counselling (NCIT:C15240): the essential preventive intervention. Must cover: de novo origin, ~50% transmission risk from an affected individual, low sibling recurrence risk, the SWCOS-vs-SCS distinction (so the family is not given SCS prognostic information), and the limits of what is known from three patients.

Behavioural, public-health, environmental interventions, prophylaxis

Not applicable, except the asplenia antibiotic prophylaxis noted above.

14. Other Species / Natural Disease

• Species affected (natural disease): none known. No naturally occurring Sweeney-Cox syndrome has been reported in any non-human species. Nothing in OMIA corresponds to it.
• Breed (VBO): not applicable.
• Orthologous genes:

• Veterinary relevance: none. TWIST1-adjacent note of comparative interest: a severe craniofacial phenotype in Burmese cats is caused by homozygous disruption of Alx1 — the gene TWIST1 directly regulates through the ECR1 enhancer [CACHED, PMID:41850652, citing Lyons et al. 2016]. This is a natural animal model of the downstream node, not of SWCOS itself, and should not be curated as a SWCOS animal model.
• Comparative pathology: the mouse Twist1 neural-crest conditional knockout reproduces the direction of the human defect — loss of snout, upper face and skull vault bones — but as a recessive tissue-specific null, not as a dominant-negative heterozygote.
• Evolutionary conservation: exceptional. The glutamate is conserved from C. elegans HLH-8 (Glu29) through Drosophila Twist to human TWIST1 (Glu117) and TWIST2 (Glu75). This conservation is what licensed the worm allelic series and is itself the strongest a priori evidence for pathogenicity.
• Zoonotic potential / cross-species transmission: not applicable.

15. Model Organisms

15.1 Caenorhabditis elegans — the definitive SWCOS model

This is the only model organism in which the actual SWCOS disease alleles have been engineered and studied, and it is the source of the dominant-negative conclusion.

• Model type: invertebrate; CRISPR-engineered knock-in allelic series at the endogenous hlh-8 locus.
• Rationale: C. elegans has a single Twist homolog (hlh-8), eliminating the paralogue redundancy that confounds vertebrate models, and permitting single-cell-resolution readouts in the developing mesoderm.
• Alleles engineered: all five human disease substitutions at the equivalent Glu29 residue — Glu29Val and Glu29Gly (SWCOS), Glu29Ala and Glu29Gln (Barber–Say), Glu29Lys (AMS). A Glu29Asp allele corresponding to the Takenouchi patient is also described in this line of work [UNVERIFIED — confirm which paper generated the Asp allele before citing].
• Readouts: target-gene expression in vulval and enteric muscle; constipation/defecation defect; egg-laying/embryo-retention phenotype.
• Result — graded severity:

  "This allelic series revealed that different substitutions exhibit graded severity, in terms of both gene expression and cellular phenotype, which we incorporate into a model explaining the various human disease phenotypes." — PMID:28369379 [CACHED]

Reported ordering, most to least severe: Glu29Lys (AMS) > Glu29Val (and Glu29Asp) > Glu29Gly ≈ Glu29Ala ≈ Glu29Gln, with the weaker alleles retaining residual target-gene expression (74–100% in intestinal muscles) [WEB — PMC5438873]. - Dominant-negative evidence: hlh-8 null alleles behave recessively, whereas all Glu29 heterozygotes showed semi-dominant embryo retention and reduced target-gene expression in vulval muscle — i.e. the mutant proteins interfere with wild-type HLH-8 [WEB — PMC5438873]. This heterozygote-vs-null contrast is the crux of the argument and is exactly what a RECAPITULATES link with a mechanism-level target should point at. - Tissue-specific sensitivity: vulval muscles (heterodimer-dependent) were more sensitive than enteric muscles (where HLH-8 homodimers matter) [WEB] — an elegant internal control showing the defect is dimer-context-dependent. - Phenotype recapitulation: excellent for mechanism, nil for morphology. The worm reproduces the molecular logic (allele-specific graded antimorphism, heterozygous interference) but has no craniofacial structures, no neural crest, and no vertebrate skeleton. This is the textbook case for PARTIALLY_RECAPITULATES with an explicit limitations string. - Suggested dismech link: yaml animal_models: - name: C. elegans hlh-8 Glu29 disease-allele series species: Caenorhabditis elegans genotype: hlh-8(Glu29Val), hlh-8(Glu29Gly) knock-in heterozygotes and homozygotes publication: PMID:28369379 modeled_mechanisms: - target: <the dominant-negative dimer-sequestration node> relationship: PARTIALLY_RECAPITULATES fidelity: MODERATE limitations: >- C. elegans has no neural crest, no craniofacial skeleton, and no vertebrate suture biology; the model recapitulates the allele-specific antimorphic logic and heterozygous interference, not the human frontonasal phenotype. Readouts are mesodermal muscle lineages. - Database: WormBase.

15.2 Mouse — the gene model, not the disease model

No mouse carrying a Twist1 Glu117-equivalent knock-in has been reported. This is the single largest experimental gap for SWCOS.

Curation warning. The temptation to attach Twist1^+/− mice to a Sweeney-Cox entry should be resisted — that genotype models haploinsufficiency, the mechanism SWCOS explicitly is not. If included at all, it belongs with relationship: FAILS_TO_RECAPITULATE against the dominant-negative node, with limitations and evidence supplied (both required for that relationship value by test_failure_to_recapitulate_links_are_substantiated).

15.3 Zebrafish

• ZFIN carries the human disease term ZDB-TERM-190716-1 for Sweeney-Cox syndrome with no genes and no models registered [WEB].
• A zebrafish twist model of Saethre-Chotzen craniosynostosis exists (altered bone growth dynamics prefiguring suture fusion) [WEB — PMC6207424] — again, SCS not SWCOS.
• The paralogue duplication (twist1a/twist1b) makes zebrafish a poorer choice than C. elegans for a dominant-negative allelic series.

15.4 Cellular / in vitro systems

• hPSC-derived cranial neural crest cells (hCNCCs) — the most promising unexploited system. The Coordinator-motif work (PMID:38262408) and the TF-dosage work (PMID:40020686) both use hCNCC differentiation and directly interrogate TWIST1 binding, chromatin opening, and dose-response. Knocking a p.Glu117Val allele into hPSCs and differentiating to CNCC would be the single highest-value experiment for this disease and is, as far as I can determine, not yet published.
• Structural/biophysical: PDB 8OSB (TWIST1–TCF4–ALX4 on DNA) supports in silico modelling of E117V/G/D.
• Patient-derived lines: none reported. No fibroblast or iPSC line from any of the three patients is described or deposited.

15.5 Applications and gaps

Answerable with existing models: the dominant-negative-vs-null distinction; graded allele severity; the TWIST1→ALX1 regulatory edge; CNCC EMT/migration/survival requirements; suture biology.

Not answerable with existing models — recommended discussions entries: - HUMAN_MODEL_MISMATCH — the antimorphic mechanism is demonstrated only in C. elegans mesodermal muscle; it has never been tested in a vertebrate craniofacial context, and no mammalian model of a Glu117-equivalent substitution exists. - KNOWLEDGE_GAP — why is the frontonasal/periocular region specifically vulnerable, when TWIST1 is expressed throughout CNCCs and pharyngeal arches? (The Coordinator/homeodomain-partner hypothesis is the leading answer but is untested for Glu117.) - KNOWLEDGE_GAP — is the developmental delay intrinsic (cerebellar hypoplasia, CNS TWIST1 function) or secondary (hearing loss, hospitalization, airway)? - KNOWLEDGE_GAP — does a Glu117 substitution affect the non-nuclear, β/δ-catenin-associated TWIST1 pool described in PMID:35781329? - KNOWLEDGE_GAP — Takenouchi's lethality conjecture: are the three known patients the survivable tail of the codon-117 allelic series?

Curation appendix — ready-to-use evidence items

These snippets are exact substrings of files already in references_cache/ and will pass just count-verified-snippets / just validate-references without further fetching. Everything else in this report must be fetched with just fetch-reference <ID> before it can be quoted.

# Disease definition / delineation
- reference: PMID:28369379
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "Here, we describe a new clinical entity, Sweeney-Cox syndrome, associated with distinct de novo amino acid substitutions (p.Glu117Val and p.Glu117Gly) at a highly conserved glutamic acid residue located in the basic DNA binding domain of TWIST1, in two subjects with frontonasal dysplasia and additional malformations."
  explanation: Delineates the entity and its two founding de novo TWIST1 alleles.

# Codon-117 specificity vs the SCS mutation spectrum
- reference: PMID:28369379
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "Although about one hundred different TWIST1 mutations have been reported in patients with the dominant haploinsufficiency Saethre-Chotzen syndrome (typically associated with craniosynostosis), substitutions uniquely affecting the Glu117 codon were not observed previously."
  explanation: Establishes codon 117 as a distinct hotspot separate from the SCS haploinsufficiency spectrum.

# Dominant-negative mechanism
- reference: PMID:28369379
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "The genetic analysis favors a predominantly dominant-negative mechanism for the action of amino acid substitutions at this highly conserved glutamic acid residue"
  explanation: C. elegans allelic series supports antimorphic rather than loss-of-function action.

# Graded severity across the allelic series
- reference: PMID:28369379
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "This allelic series revealed that different substitutions exhibit graded severity, in terms of both gene expression and cellular phenotype, which we incorporate into a model explaining the various human disease phenotypes."
  explanation: Basis for the activity-continuum model relating substituting residue to disease.

# Antimorphic effect shared with the TWIST2 disorders
- reference: PMID:30450715
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "Heterozygous localized TWIST1 and TWIST2 basic domain substitutions exert antimorphic effects to cause Sweeney-Cox syndrome, Barber-Say syndrome, and ablepharon-macrostomia syndrome, respectively."
  explanation: Independent statement of the antimorphic mechanism across the paralogous hotspots.

# Third patient: craniosynostosis + ablepharon with p.Glu117Asp
- reference: PMID:30450715
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "Herein, we document a male infant with the distinctive facial features of ablepharon, hypertelorism, cheek pads adjacent to the corners of the mouth, and bilateral coronal suture craniosynostosis who had a de novo heterozygous mutation in the basic domain of TWIST1, that is, c.351C>G p.Glu117Asp."
  explanation: Extends the phenotype to include craniosynostosis and adds the third causal allele.

# The SWCOS / SCS boundary
- reference: PMID:30450715
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "Our review showed that Sweeney-Cox syndrome appears to share many characteristics with Barber-Say syndrome and ablepharon-macrostomia syndrome except for craniosynostosis, which is a cardinal feature of Saethre-Chotzen syndrome."
  explanation: Positions SWCOS in the differential against the TWIST2 disorders and SCS.

# Mild-antimorph model for the Asp allele
- reference: PMID:30450715
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "The present observation suggests that a localized TWIST1 basic domain substitution, that is, p.Glu117Asp, in TWIST1 may exert a mild antimorphic effect similar to that of haploinsufficiency, leading to craniosynostosis and ablepharon."
  explanation: Supports the dose-continuum edge linking milder antimorphism to a synostosis phenotype.

# Inheritance
- reference: PMID:39502847
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: "The pattern of inheritance is autosomal dominant in Saethre-Chotzen syndrome, Robinow-Sorauf syndrome, and Sweeney-Cox syndrome."
  explanation: Confirms autosomal dominant inheritance for SWCOS.

# Twist1 requirement in frontonasal / skull vault development (mouse)
- reference: PMID:19414008
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "Loss of Twist1 in neural crest cells and their derivatives impairs skeletogenic differentiation and leads to the loss of bones of the snout, upper face and skull vault."
  explanation: Mouse NCC-conditional null supports the neural-crest skeletogenic node.

# Non-cell-autonomous extension to mesodermal bone
- reference: PMID:19414008
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "The effect of the loss of Twist1 function is not restricted to neural crest-derived bones, since the predominantly mesoderm-derived parietal and interparietal bones are also affected, presumably as a consequence of lost interactions with neural crest-derived tissues."
  explanation: Supports a non-cell-autonomous edge from NCC dysfunction to mesoderm-derived skull vault bone.

# TWIST1 in CNCC EMT
- reference: PMID:35781329
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "Twist1 suppresses Irf6 and other epithelial genes in CNCCs during the epithelial-to-mesenchymal transition (EMT) process and cell migration. Conversely, a loss of Twist1 leads to a sustained expression of epithelial and cell adhesion markers in migratory CNCCs."
  explanation: Supports the EMT/migration node downstream of TWIST1 dysfunction.

# TWIST1 as a CNCC survival/proliferation factor
- reference: PMID:35781329
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "TWIST1 has been shown to promote cell survival and proliferation of migratory CNCCs during craniofacial development"
  explanation: Supports the CNCC survival node in the causal chain.

# SWCOS vs SCS phenotype framing (2026)
- reference: PMID:41850652
  supports: SUPPORT
  evidence_source: OTHER
  snippet: "Mutations in TWIST1 have been associated with Sweeney-Cox (OMIM 617746) and Saethre-Chotzen (OMIM 101400) syndromes, with Sweeney-Cox syndrome characterized by hypertelorism with severe deficiency in frontal bones and hypoplasia of the nose and facial bones while Saethre-Chotzen syndrome exhibits craniosynostosis with hypertelorism and maxillary hypoplasia"
  explanation: Current framing of the SWCOS phenotype in contrast with SCS.

# TWIST1 -> ALX1 regulatory edge
- reference: PMID:41850652
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: "mice with lineage-specific inactivation of Twist1 in migrating neural crest cells, exhibited dramatic loss of Alx1 mRNA expression in the developing frontonasal CNCCs"
  explanation: Supports the causal edge from TWIST1 dysfunction to failure of the frontonasal ALX gene program.

The finding that most changes how this entry should be written

ClinGen's Craniofacial Malformations GCEP evaluated TWIST1 against three separate disease assertions and reached three different verdicts — Definitive for Saethre-Chotzen, Moderate for TWIST1-related craniosynostosis, and Limited for Sweeney-Cox:

"Three rare but clinically defined and distinguishable gene-disease pairs were found to have Limited evidence ranging from 3 to 4 points to support the relationship by the Cranio GCEP: FGFR1-related osteoglophonic dysplasia (OMIM:166250), TWIST1-related Sweeney-Cox syndrome (OMIM:617746), and FGFR2 and lacrimo-auriculo-dento-digital (LADD) syndrome (OMIM:149730)" — Edoh EYA, et al. Genet Med 2026. PMID:42059179 [CACHED]

with the operational consequence spelled out in the same paper:

"According to ACMG technical standards, genes classified as Moderate, Strong, or Definitive are eligible for inclusion in diagnostic testing panels, whereas those below this threshold should not be considered." — PMID:42059179 [CACHED]

Two things follow. First, this is a clinically distinguishable entity with a well-supported mechanism whose gene–disease validity is nonetheless formally Limited — the constraint is case count (3), not evidence quality, and the paper is explicit that Moderate and Limited curations are revisited every three years. Second, a dismech entry that presents SWCOS with the same confidence as a Definitive relationship would be overstating the field's own position. State the Limited classification in the entry, cite it, and let the mechanism sections carry the weight they legitimately can.

Sources

• Kim S, Twigg SRF, et al. Localized TWIST1 and TWIST2 basic domain substitutions cause four distinct human diseases that can be modeled in Caenorhabditis elegans. Hum Mol Genet 2017 — PMID:28369379 · full text PMC5438873 · Oxford Academic
• Takenouchi T, et al. Ablepharon and craniosynostosis in a patient with a localized TWIST1 basic domain substitution. Am J Med Genet A 2018 — PMID:30450715
• Edoh EYA, et al. Evidence-based classification of genes implicated in craniosynostosis disorders using the ClinGen curation framework. Genet Med 2026 — PMID:42059179
• Huang Y, et al. A Twist1-regulated distal enhancer crucial for Alx1 gene expression and function during craniofacial development. Dev Biol 2026 — PMID:41850652
• Dhiman S, et al. TWIST1 Gene Variants Cause Craniosynostosis with Limb Abnormalities in Asian Patients. J Pediatr Genet 2024 — PMID:39502847
• Bertol JW, et al. TWIST1 interacts with β/δ-catenins during neural tube development. Development 2022 — PMID:35781329
• Bildsoe H, et al. Requirement for Twist1 in frontonasal and skull vault development in the mouse embryo. Dev Biol 2009 — PMID:19414008
• DNA-guided transcription factor cooperativity shapes face and limb mesenchyme. Cell 2024 — PMID:38262408
• Marchegiani S, et al. Recurrent Mutations in the Basic Domain of TWIST2 Cause Ablepharon Macrostomia and Barber-Say Syndromes. Am J Hum Genet 2015 — PMID:26119818
• The ALX4 dimer structure provides insight into how disease alleles impact function. Nat Commun 2025 — PMID:40410151
• Inhibition of craniosynostosis and premature suture fusion in Twist1 mutant mice with RNA nanoparticle gene therapy. Sci Adv 2025
• OMIM #617746 — Sweeney-Cox syndrome · Clinical Synopsis · OMIM *601622 TWIST1
• HPO annotations for OMIM:617746 (ontology.jax.org API)
• UniProt Q15672 — TWIST1_HUMAN · HGNC:12428 · RCSB PDB 8OSB
• ClinVar — TWIST1 variants at codon 117
• GTR condition C4540299 — Sweeney-Cox syndrome · Disease Ontology DOID:0080538 · ZFIN human disease term
• Hereditary Ocular Diseases — Sweeney-Cox Syndrome (Univ. of Arizona)

Next step: if you want this turned into the KB entry, the highest-value first pass is the pathophysiology chain in §6.1 — nine nodes with biological_scale tags already assigned, the GO:0070888 E-box-binding-lost / GO:0046983 dimerization-retained contrast as the mechanistic core, and eleven cache-verified snippets ready to attach. Say the word and I'll draft it against the untracked kb/disorders/Sweeney-Cox_Syndrome.yaml on this branch.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:40020686 (abstract only): "how concentrations of the dosage-sensitive TFs TWIST1 and SOX9 affect regulatory element chromatin accessibility in facial progenitor cells"
• closest text in source: "We applied transfer learning to predict how concentrations of the dosage-sensitive TFs TWIST1 and SOX9 affect regulatory element (RE) chromatin accessibility in facial progenitor cells, achieving near-experimental accuracy"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• DOID:0080538 (4 mentions) - the report calls it "Disease Ontology"; DOID calls it Sweeney-Cox syndrome
• NCIT:C15329 (10 mentions) - the report calls it "Nasal airway", "Craniosynostosis (E117D patient)", "Orbital bone deficiency, hypertelorism", "Cleft palate, velopharyngeal insufficiency", "Imperforate anus", "Bilateral cryptorchidism", "Microtia", "Feeding failure"; NCIT calls it Surgical Procedure
• NCIT:C16186 (2 mentions) - the report calls it "Bilateral talipes equinovarus"; NCIT calls it Orthopedic Surgical Procedure

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002023 (1 mention) - the report calls it "Anal atresia (imperforate anus)"; HP calls it Anal atresia**, and lists "Imperforate anus" among its other names
• HP:0003577 (3 mentions) - the report calls it "Congenital onset (2/2)"; HP calls it Congenital onset**
• GO:0006357 (1 mention) - the report calls it "Regulation of transcription by RNA Pol II"; GO calls it regulation of transcription by RNA polymerase II
• CL:0000333 (1 mention) - the report calls it "migratory cranial neural crest cell"; CL calls it migratory neural crest cell
• NCBITaxon:6239 (1 mention) - the report calls it "C. elegans"; NCBITaxon calls it Caenorhabditis elegans, and lists "Rhabditis elegans" among its other names
• NCBITaxon:7227 (1 mention) - the report calls it "Drosophila"; NCBITaxon calls it Drosophila melanogaster

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• NCIT:C15329 - called "Nasal airway", "Craniosynostosis (E117D patient)", "Orbital bone deficiency, hypertelorism", "Cleft palate, velopharyngeal insufficiency", "Imperforate anus", "Bilateral cryptorchidism", "Microtia", "Feeding failure"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, OMIM.